Current Report Filing (8-k)
April 18 2017 - 1:48PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April
18, 2017
BIOSPECIFICS TECHNOLOGIES
CORP.
(Exact name of registrant as specified in its
charter)
Delaware
|
001-34236
|
11-3054851
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
35 Wilbur Street
|
11563
|
Lynbrook, NY
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrants telephone number, including area code:
516.593.7000
N/A
(Former name or former address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
Introductory Comment
Throughout this Current Report on Form 8-K, the terms we,
us, our and Company refer to BioSpecifics Technologies Corp.
On April 18, 2017, BioSpecifics announced the initiation of its
Phase 1 clinical trial of XIAFLEX® for the treatment of uterine fibroids.
A press release regarding the announcement is attached as
Exhibit 99.1 to this Current Report on Form 8-K.
Item
9.01.
|
Financial Statements and Exhibits
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: April 18, 2017
|
|
|
|
BioSpecifics Technologies Corp.
|
|
|
|
By:
/s/ Thomas L. Wegman
|
|
Name: Thomas L. Wegman
|
|
Title:
President
|
3
EXHIBIT INDEX
4
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Apr 2023 to Apr 2024